Biologic therapy in pediatric inflammatory bowel disease

Patel Sonal, Jennifer Strople*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


The incidence of pediatric inflammatory bowel disease (IBD) has risen over the past several decades and therapeutic strategies continue to evolve. Many unique considerations must be taken into account when selecting the optimal therapy for a pediatric IBD patient, including the effect of therapy on growth parameters, the cummulative or long-term adverse effects of treatments, and the inherently longer duration of therapy give the young age at diagnosis. Biologic agents have been used to treat pediatric IBD for several decades. This chapter reviews the biologic agents currently used to treat this population, the indications for use in pediatric Crohn’s disease (CD) and ulcerative colitis (UC), outcomes associated with these medications, including impact on growth and bone health, and adverse events, specfically malignancy risks. Strategies and recommendations for vaccination of peidatric IBD patients receiving biologic therapy are also reviewed.

Original languageEnglish (US)
Title of host publicationTreatment of Inflammatory Bowel Disease with Biologics
PublisherSpringer International Publishing
Number of pages21
ISBN (Electronic)9783319602769
ISBN (Print)9783319602752
StatePublished - Jan 1 2017


  • Anti-TNF therapy
  • Anti-integrin therapy
  • Growth failure
  • Hepatosplenic T-cell lymphoma
  • Infliximab
  • Pediatric Crohn’s disease
  • Pediatric Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Biologic therapy in pediatric inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this